Table 6.
Studies without the inclusion criteria.
| Reference | Molecule | CoQ10 mg/d |
Duration (d: Days) | Placebo | n Total/CoQ10 |
Type of Subjects | Sex | Sport/Activity | Exercise Testing | Age (Years) | Impact on Phys./Sport Perf. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drobnic et al. (2020) | [47] | Ubiquinone | 100 | 30 d | Control | 20/12 | Well trained subjects | Male | Marathon runners | Treadmill Hot & Humid environment | 55 ± 4 | Yes |
| Emami et al. (2018) | [48] | Ubiquinone | 300 | 14 d | Yes | 36/9 | Well trained subjects | Male | Swimmwers | Swimming training | 18 ± 1 | |
| Fiorella et al. (1991) | [49] | Ubiquinone | 100 | 40 d | Control | 22/11 | Well trained subjects | Male | Athletes | Graded max test + Incremental running test until exhaustion | 29 ± 6 | Yes |
| García-Verazaluce et al. (2015) | [50] | Ubiquinone + | 120 + Phlebodium d. | 28 d | Yes | 30/10 | Well trained subjects | Male | Volleyball | None | 25 ± 2 | Ns |
| Geiss et al. (2004) | [51] | Ubiquinone | 180 | 28 d | Yes | 10/10 | Well trained subjects | Male? | Endurance | Submaximal fatigue test | Ns | Yes |
| Gökbel et al. (2010) | [52] | Ubiquinone | 100 | 56 d | Yes | 15/15 | Non active | Male | Ns | Anaerobic test(Repeated Wingate test) | 20 ± 1 | No |
| Gökbel et al. (2016) | [53] | Ubiquinone | 200 | 98 d | Yes | 23/23 | Patients (hemodyalisis) | Male | Ns | 6 Mins walking test | 47 ± 12 | No |
| Guerra et al. (1987) | [54] | Ubiquinone | 60 | 35 d | Ns | Moderately trained subjects | Male | Cycling | Graded max test. Race 9 km. | Ns | Yes/Yes | |
| Gül et al. (2011) | [55] | Ubiquinone | 100 | 56 d | Yes | 15 | Non active | Male | - | Anaerobic repeated tests | 20 ± 1 | Yes |
| Kaikkonen et al. (1998) | [57] | Ubiquinone + |
90 + Vit E | 21 d | Yes | 37/18 | Moderately trained subjects | Male | Marathon | Marathon | 40 ± 7 | No |
| Laaksonen et al. (1995) | [58] | Ubiquinone + |
120 + Omega 3 |
42 d | Yes | 11/11 | Well trained subjects | Male Male |
Marathon & triathletes | Graded max. test | 28 (22–38) |
No |
| 8/8 | 64 (60–74) |
No | ||||||||||
| Leelarungrayub (2010) | [59] | Ubiquinone | 300 | 12 d | No | 16/16 | Moderately trained subjects | Male & Female | Swimmimg | Treadmill time to exhaustion & Swimmimg 100–800 m | 15 ± 1 | Yes 100 m, No 800 m |
| Malm et al. (1996) | [60] | Ubiquinone | 120 | 20 d | Yes | 15/9 | Moderately trained subjects | Male | - | Anaerobic tests | 20–34 | No |
| Malm et al. (1997) | [61] | Ubiquinone | 120 | 22 d | Yes | 18/9 | Moderately trained subjects | Male | - | Graded max and Anaerobic tests | 25 ± 3 | No |
| Mizuno et al. (2008) | [62] | Ubiquinone | 100 & 300 | 56 d | Yes | 17/17 | Physically active subjects | Male & Female | - | Anaerobic repeated tests under fatigue | 38 ± 10 | Yes |
| Nielsen et al. (1999) | [63] | Ubiquinone + |
100 + Vit E & Vit C | 42 d | Yes | 7/7 | Well trained subjects | Male | Triathletes | Graded max. & Local fatigue (31P-NMRS) | 22–32 | No |
+: indicates that the administration of Ubiquinone is supplemented by one or more other substances (indicated in the next column).